Skip to Content

The MD Anderson Symptom Inventory Lung Cancer Module (MDASI-LC)

ORDER ASSESSMENT TOOLS

MD Anderson Symptom Inventory (MDASI) modules augment the 19 core MDASI symptom and interference items with additional items identified as unique to a particular patient population. MDASI modules may be disease-specific, disease-site-specific, or treatment-specific.

The MDASI-LC is a site-specific module. Along with the core MDASI’s 13 symptom items and 6 interference items, the MDASI-LC also assesses 3 lung cancer-specific symptom items: coughing, constipation, and sore throat.

MDASI-LC Features

  • Purpose: To assess the severity of multiple lung cancer-related symptoms and the impact of these symptoms on daily functioning
  • Population: Patients with symptoms caused by lung cancer and its treatment
  • Assessment areas: Severity of multiple symptoms and the impact of symptoms on daily functioning during the last 24 hours
  • Method: Self-report; paper-and-pencil form or tablet PC (self-administered or via interview), or telephone-based interactive voice response (IVR) system
  • Time required: Five minutes
  • Scoring: Please see the MDASI User's Guide
  • Reliability: Cronbach alpha reliability ranges from 0.88 to 0.91

MDASI-LC Language Versions

The MDASI-LC is available in the languages shown below. Click on a linked language to view a sample in PDF format.

Psychometrically and Linguistically ValidatedLinguistically Validated
EnglishDutch
Serbian

Future Validation Studies: We would like to collaborate with other investigators to develop and validate new language versions of the MDASI-LC. Contact us for more information. NOTE: The MDASI-LC may not be modified or translated into another language without express written consent (see Notice of Copyright below).

To Order the MDASI-LC

To use the MDASI-LC in a publication or clinical or research trial, you must obtain permission by filling out our order form and you must comply with the copyright. Fees may apply:

Type of UseFirst Language Version (Per Project)Additional Language Versions (Per Project)
Non-funded academic researchNo chargeNo charge
Individual clinical practiceNo chargeNo charge
Funded academic research$300$150
Commercial research$2,000$1,200

 
The MDASI-LC will be e-mailed to you as a PDF file within 7 to 10 business days. If your request is urgent or the language version you seek is not shown, contact us to make special arrangements:

Department of Symptom Research
Attn: Assessment Tools
The University of Texas MD Anderson Cancer Center
1515 Holcombe Boulevard, Unit 1450
Houston, Texas 77030
symptomresearch@mdanderson.org  

If applicable, an invoice will be e-mailed to you. Reference the invoice number on your payment and include on the memo line, "MD Anderson Assessment Tool Distribution."

Notice of Copyright

The M. D. Anderson Symptom Inventory (MDASI) copyright is held by The University of Texas MD Anderson Cancer Center and administered by the MDASI's developer, Charles S. Cleeland, PhD. The copyright applies to the MDASI, its modules, and all its derivatives in any language.

The MDASI-LC may not be used or reproduced without permission from Charles S. Cleeland, PhD, or his designee. Fees for use may apply (see above).

The MDASI and its modules may not be modified or translated into another language without the express written consent of the copyright holder. Failure to comply may result in legal action. Contact us via e-mail at symptomresearch@mdanderson.org or at the address shown above to obtain permission to alter or translate the instrument.

Selected References

Validation

Mendoza TR, Wang XS, Lu C, Palos GR, Liao Z, Mobley GM, Kapoor S, Cleeland CS. Measuring the symptom burden of lung cancer: the validity and utility of the lung cancer module of the M. D. Anderson Symptom Inventory. Oncologist 16(2): 217-227, 2011.

Cleeland CS, Mendoza TR, Wang XS, Chou C, Harle M, Morrissey M, & Engstrom MC. Assessing Symptom Distress in Cancer: The M. D. Anderson Symptom Inventory. Cancer 89:1634-1646, 2000.

Clinical Application

Jones D, Vichaya EG, Wang XS, Mendoza TR, Mobley GM, Lu C, Cleeland CS. Disease-driven symptoms and response to chemotherapy in treatment-naive patients with advanced non-small cell lung cancer (NSCLC) [abstract]. American Society of Clinical Oncology 48th Annual Meeting, Chicago IL, Jun 1-5, 2012. J Clin Oncol 30(Suppl 1), 2012; 9118.

Wang XS, Shi Q, Lu C, Basch EM, Johnson VE, Mendoza TR, Mobley GM, Cleeland CS. Prognostic value of symptom burden for overall survival in patients receiving chemotherapy for advanced nonsmall cell lung cancer. Cancer 116(1): 137-145, 2010.

Related News

Symptom Research hosts national colloquium on developing strategies for reducing cancer treatment-related toxicities and symptoms. Read more...

 Cancer Symptom Science

Announcing the publication of Cancer Symptom Science, an interdisciplinary, first-of-its-kind compilation of research on the mechanisms underlying the expression of cancer-related symptoms. Read more...

Old Drugs, New Possibilities (Conquest, Fall 2008)

Symptom Research Awarded NIH P01 Grant (Division of Internal Medicine Newsletter, Summer 2008)

Symptom Research and Psychometrics (Network, Summer 2008)


© 2014 The University of Texas MD Anderson Cancer Center